Please ensure Javascript is enabled for purposes of website accessibility

Quest Diagnostics to Double U.S. Coronavirus Testing Capacity by Mid-May

By Cory Renauer – Apr 22, 2020 at 3:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

During an otherwise disappointing earnings call, management made one encouraging prediction.

One of the country's largest clinical laboratory operators, Quest Diagnostics (NYSE: DGX) says that by mid-May, it will have enough capacity in the U.S. to perform over 200,000 COVID-19 antibody tests per day. Management made that forecast during Wednesday's  otherwise depressing first-quarter earnings call. 

On Tuesday, Quest Diagnostics began performing tests for the antibodies produced by immune systems that are fighting off SARS-CoV-2, the coronavirus responsible for COVID-19. There's nothing necessarily wrong with antibody tests, but they aren't much use when it comes to a virus containment effort, nor for immediate diagnostic purposes. People don't usually develop the antibodies that Quest is testing for until 14 days after they have started to show symptoms. They can, however, help shed light on how widely the coronavirus has spread, and whether those who have recovered from COVID-19 have some degree of protection from reinfection.

Lab tech loading a rack of sample tubes.

Image source: Getty Images.

There's a good chance Quest Diagnostics can double the capacity for coronavirus testing in the U.S. within a few short weeks. The number of tests performed daily peaked on April 4 at 229,268. During the week ended April 21, the COVID Tracking Project recorded an average daily volume of just 153,365 tests.

Not there yet

Public health officials around the world agree that adequate testing is a prerequisite to governments being able to safely relax stay-at-home orders. Epidemiologists generally say they want to see less than 2% of COVID-19 tests coming back positive -- results at that level would suggest that everybody who should be getting tested is getting tested. If the rate of positive results is more than 10%, it's an indication that access to testing is too limited for the country to avoid another surge of outbreaks.

During the past week, around 18% of U.S. COVID-19 tests performed came back positive. Efforts by Quest and its peers will go a long way to help lower that percentage, but it's going to be a while before we can hang out again without risking each other's lives.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
DGX
$122.69 (-1.55%) $-1.93

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.